close
About Ubix
Ubix Therapeutics develops novel anti-cancer drugs based on Degraducer® platform technology.
Degraducer® is a powerful, next-generation inhibitor technology that enables targeting of disease-related targets that were previously undruggable.
We are developing novel anti-cancer therapies based on conscientious research and understanding of the human immune system and target proteins. Our goal is to increase life span and improve quality of life for affected patients.
BK Seo
Chief Executive Officer
BK Seo founded and has been serving as Chief Executive Officer of Ubix Therapeutics since June 2018. For over 20 years, he has conducted many projects in the bio/pharmaceutical industry, most notably, in R&D planning, business development, and funding.
Song-Hee Lee, Ph.D.
Research Director
SH Lee is the research director at Ubix Therapeutics. She joined Ubix in October of 2018 after more than a decade of research experience in academia as a molecular virologist.
Je-Ho Ryu, Ph.D
Vice Research Director
JH Ryu is the director of Medicinal Chemistry and vice research director at Ubix Therapeutics. He joined Ubix in January of 2019 after 20 years in the pharmaceutical industry.
Bo-Sun Suh
Chief Financial Officer
BS Suh, the CFO of Ubix Therapeutics, has served as a financial specialist for over 21 years in diverse industries including venture and finance.
Hye-Suk Hong
Director, Chemistry, Manufacturing, and Controls
HS Hong is the director of Chemistry, Manufacturing, and Controls at Ubix Therapeutics. Ms. Hong holds over 21 years of broadly diversified experience in pharmaceutical industry.
Joo-Yeop Kim
IP Counsel
JY Kim serves as the IP counsel and the general counsel at Ubix Therapeutics. He joined Ubix in March 2019 after working as the expert advisor for Korea Intellectual Property Protection Agency.